FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Markolf Hanefeld

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Activities & Behaviors

Fasting

Co-author Network

Publications

TOP 3
Markolf Hanefeld; Peter Bramlage
Insulin Use Early in the Course of Type 2 Diabetes Mellitus: The ORIGIN Trial.
Matthias Weck; Andreas Barthel; Stefan Bornstein; Andrej Brechow; Ulf Dietrich; Georg von Gagern; Mandy Holfert; Carsta Koehler; Dirk Muench; Thomas Nanning; Hartmut Paetzold; Torsten Slesaczeck; Antje Thomas; Markolf Hanefeld
Structured health care for subjects with diabetic foot ulcers results in a reduction of major amputation rates.
Anselm K Gitt; Martin Halle; Markolf Hanefeld; Monika Kellerer; Nikolaus Marx; Juris J Meier; Petra-Maria Schumm-Draeger; Peter Bramlage; Diethelm Tschöpe
Should antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without?

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Markolf Hanefeld (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Markolf Hanefeld; Peter Bramlage
Insulin Use Early in the Course of Type 2 Diabetes Mellitus: The ORIGIN Trial.
Current diabetes reports 2013;13(3):342-9.
2013: Matthias Weck; Andreas Barthel; Stefan Bornstein; Andrej Brechow; Ulf Dietrich; Georg von Gagern; Mandy Holfert; Carsta Koehler; Dirk Muench; Thomas Nanning; Hartmut Paetzold; Torsten Slesaczeck; Antje Thomas; Markolf Hanefeld
Structured health care for subjects with diabetic foot ulcers results in a reduction of major amputation rates.
Cardiovascular diabetology 2013;12():45.
2012: Anselm K Gitt; Martin Halle; Markolf Hanefeld; Monika Kellerer; Nikolaus Marx; Juris J Meier; Petra-Maria Schumm-Draeger; Peter Bramlage; Diethelm Tschöpe
Should antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without?
European journal of heart failure 2012;14(12):1389-400.
2012: Markolf Hanefeld; Carsta Koehler; Frank Pistrosch; Jean Louis Chiasson
Conversion of IGT to type 2 diabetes mellitus is associated with incident cases of hypertension: a post-hoc analysis of the STOP-NIDDM trial.
Journal of hypertension 2012;30(7):1440-3.
2012: Tsvetan Stefanov; Theodora Temelkova-Kurktschiev; Elena Henkel; Carsta Koehler; Frank Schaper; Markolf Hanefeld
Association of physical activity with insulin resistance, subclinical inflammation, coagulation, and fibrinolytic biomarkers among population at high risk for type 2 diabetes.
Folia medica 2012;54(2):32-9.
2012: David Russell-Jones; Anne M Wolka; Marilyn K Boardman; Melanie Chan; Robert M Cuddihy; Jose G González; Markolf Hanefeld; Ajay Kumar
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
Diabetes care 2012;35(2):252-8.
2011: Andreas Pfützner; Lida A Dekordi; Winfried Fuchs; Markolf Hanefeld; Iris Kleine; Jürgen Müller; Thomas Forst
Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study.
Journal of diabetes science and technology 2011;5(4):989-98.
2011: Thomas Forst; Markolf Hanefeld; Andreas Pfützner
Review of approved pioglitazone combinations for type 2 diabetes.
Expert opinion on pharmacotherapy 2011;12(10):1571-84.
2011: Michael R MacDonald; Mark C Petrie; Philip D Home; Michel Komajda; Nigel P Jones; Henning Beck-Nielsen; Ramon Gomis; Markolf Hanefeld; Stuart J Pocock; Paula S Curtis; John J V McMurray
Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study.
Diabetes care 2011;34(6):1394-6.
2011: Annett Stahn; Markolf Hanefeld
[Multimodal therapy of dyslipidemia].
Clinical research in cardiology supplements 2011;6():10-6.
2011: Frank Pistrosch; Andrea Natali; Markolf Hanefeld
Is hyperglycemia a cardiovascular risk factor?
Diabetes care 2011;34 Suppl 2():S128-31.
2011: Markolf Hanefeld; Iris Kleine; Andreas Pfützner; Thomas Forst; Winfried Fuchs
Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study.
Cardiovascular diabetology 2011;10():65.
2010: Markolf Hanefeld; Thomas Forst
Dapagliflozin, an SGLT2 inhibitor, for diabetes.
Lancet 2010;375(9733):2196-8.
2010: Andreas Pfützner; Thomas Schöndorf; Markolf Hanefeld; Thomas Forst
High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone.
Journal of diabetes science and technology 2010;4(3):706-16.
2010: Michel Komajda; John J V McMurray; Henning Beck-Nielsen; Ramon Gomis; Markolf Hanefeld; Stuart J Pocock; Paula S Curtis; Nigel P Jones; Philip D Home
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.
European heart journal 2010;31(7):824-31.
2010: Effrossyni Gkrania-Klotsas; Zheng Ye; Andrew J Cooper; Stephen J Sharp; Robert Luben; Mary L Biggs; Liang-Kung Chen; Kuppan Gokulakrishnan; Markolf Hanefeld; Erik Ingelsson; Wen-An Lai; Shih-Yi Lin; Lars Lind; Vitool Lohsoonthorn; Viswanathan Mohan; Antonio Muscari; Goran Nilsson; John Ohrvik; Jiang Chao Qiang; Nancy Swords Jenny; Koji Tamakoshi; Theodora Temelkova-Kurktschiev; Ya-Yu Wang; Chittaranjan Sakerlal Yajnik; Marco Zoli; Kay-Tee Khaw; Nita G Forouhi; Nicholas J Wareham; Claudia Langenberg
Differential white blood cell count and type 2 diabetes: systematic review and meta-analysis of cross-sectional and prospective studies.
PloS one 2010;5(10):e13405.
2009: Markolf Hanefeld; Stefan R Bornstein; Frank Pistrosch
Shifting the disease management paradigm from glucose: what are the cons?
Diabetes care 2009;32 Suppl 2():S353-6.
2009: Hana Koutnikova; Markku Laakso; Lu Lu; Roy Combe; Jussi Paananen; Teemu Kuulasmaa; Johanna Kuusisto; Hans-Ulrich Häring; Torben Hansen; Oluf Pedersen; Ulf Smith; Markolf Hanefeld; Robert Williams; Johan Auwerx
Identification of the UBP1 locus as a critical blood pressure determinant using a combination of mouse and human genetics.
PLoS genetics 2009;5(8):e1000591.
2009: Markolf Hanefeld
The role of pioglitazone in modifying the atherogenic lipoprotein profile.
Diabetes, obesity & metabolism 2009;11(8):742-56.
2009: Philip Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
Lancet 2009;373(9681):2125-35.
2009: Andreas Thomas; Martin Schönauer; Frank Achermann; Oliver Schnell; Markolf Hanefeld; Hans-Jürgen Ziegelasch; John Mastrototaro; Lutz Heinemann
The "glucose pentagon": assessing glycemic control of patients with diabetes mellitus by a model integrating different parameters from glucose profiles.
Diabetes technology & therapeutics 2009;11(6):399-409.
2009: Andreas Pfützner; Thomas Schöndorf; Markolf Hanefeld; Georg Lübben; Peter H Kann; Efstrathios Karagiannis; B Wilhelm; Thomas Forst
Changes in insulin resistance and cardiovascular risk induced by PPARgamma activation have no impact on RBP4 plasma concentrations in nondiabetic patients.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2009;41(3):202-6.
2009: P E H Schwarz; Jiang Li; Manja Reimann; Aletta E Schutte; A Bergmann; Markolf Hanefeld; Stefan R Bornstein; Jan Schulze; Jaakko Tuomilehto; Jaana Lindström
The Finnish Diabetes Risk Score is associated with insulin resistance and progression towards type 2 diabetes.
The Journal of clinical endocrinology and metabolism 2009;94(3):920-6.
2009: P E H Schwarz; Stefan R Bornstein; Markolf Hanefeld
The future of the metabolic syndrome.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2009;41(2):73-4.
2009: Frank Pistrosch; Frank Schaper; Jens Passauer; Carsta Koehler; Stefan R Bornstein; Markolf Hanefeld
Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2009;41(2):104-8.
2009: Andreas Pfützner; Karagiannis Efstrathios; Mirjam Löbig; Franz Paul Armbruster; Markolf Hanefeld; Thomas Forst
Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays--an evaluation with samples from the PIOstat study.
Clinical laboratory 2009;55(7-8):275-81.
2009: Theodora S Temelkova-Kurktschiev; Dimo P Kurktschiev; Lyudmila G Vladimirova-Kitova; Carsta Koehler; Elena Henkel; Boryana R Todorova; Frank Schaper; Katya Fuecker; Markolf Hanefeld
Pulse pressure is a strong predictor of cardiovascular risk: Data of the risk factors in impaired glucose tolerance for atherosclerosis and diabetes and the Sofia Metabolic Syndrome studies.
Folia medica 2009;51(1):34-41.
2009: Jean-Claude Ansquer; Ivan Bekaert; Martine Guy; Markolf Hanefeld; Alain Simon
Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2009;9(2):91-101.
2009: Markolf Hanefeld; Avraham Karasik; Carsta Koehler; Torsten Westermeier; Jean-Louis Chiasson
Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial.
Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease 2009;6(1):32-7.
2008: Thomas Forst; Birgit Wilhelm; Andreas Pfützner; Winfried Fuchs; Ute Lehmann; Frank Schaper; Matthias Weber; Jürgen Müller; Thomas Konrad; Markolf Hanefeld
Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk.
Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease 2008;5(4):298-303.
2008: Wolfgang Leonhardt; Andreas Pfützner; Jürgen Müller; Jens Pietzsch; Thomas Forst; Efstrathios Karagiannis; Georg Lübben; Markolf Hanefeld
Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study.
Atherosclerosis 2008;201(1):155-62.
2008: A Bergmann; J Li; Manja Reimann; T Hentrich; Markolf Hanefeld; Stefan R Bornstein; P E H Schwarz
Polymorphisms in perilipin gene (PLIN) are not associated with obesity and weight variation in people with high risk of type 2 diabetes.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2008;116 Suppl 1():S56-8.
2008: Markolf Hanefeld; Frank Schaper; Carsta Koehler
Effect of acarbose on vascular disease in patients with abnormal glucose tolerance.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2008;22(3):225-31.
2008: Ulrike Rothe; Gabriele Müller; P E H Schwarz; Martin Seifert; Hildebrand Kunath; Rainer Koch; Sybille Bergmann; Ulrich Julius; Stefan R Bornstein; Markolf Hanefeld; Jan Schulze
Evaluation of a diabetes management system based on practice guidelines, integrated care, and continuous quality management in a Federal State of Germany: a population-based approach to health care research.
Diabetes care 2008;31(5):863-8.
2008: Emile R Mohler; Christie M Ballantyne; Michael H Davidson; Markolf Hanefeld; Luis M Ruilope; Joel L Johnson; Andrew Zalewski
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Journal of the American College of Cardiology 2008;51(17):1632-41.
2008: Markolf Hanefeld; Frank Schaper
Acarbose: oral anti-diabetes drug with additional cardiovascular benefits.
Expert review of cardiovascular therapy 2008;6(2):153-63.
2008: Zvonko Milicevic; Itamar Raz; Scott D Beattie; Barbara N Campaigne; Samiha Sarwat; Elwira Gromniak; Irina Kowalska; Edvard Galic; Meng Tan; Markolf Hanefeld
Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia.
Diabetes care 2008;31 Suppl 2():S155-60.
2008: Michel Komajda; Paula Curtis; Markolf Hanefeld; Henning Beck-Nielsen; Stuart J Pocock; Andrew Zambanini; Nigel P Jones; Ramon Gomis; Philip Home
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study).
Cardiovascular diabetology 2008;7():10.
2007: Markolf Hanefeld
Is rosiglitazone associated with increased risk for cardiovascular events?
Nature clinical practice. Cardiovascular medicine 2007;4(12):648-9.
2007: Andreas Pfützner; Markolf Hanefeld; Georg Lübben; Matthias M Weber; Efstrathios Karagiannis; C Köhler; Cloth Hohberg; Thomas Forst
Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk -- results from the PIOSTAT study.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2007;39(10):764-8.
2007: Philip Home; Stuart J Pocock; Henning Beck-Nielsen; Ramón Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; john mcmurray
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
The New England journal of medicine 2007;357(1):28-38.
2007: P E H Schwarz; Stefan R Bornstein; Markolf Hanefeld
Elevated fasting glucose levels predicts IGT and diabetes also in middle-age subjects.
Diabetes research and clinical practice 2007;77(1):148-50.
2007: Markolf Hanefeld
Pioglitazone and sulfonylureas: effectively treating type 2 diabetes.
International journal of clinical practice. Supplement 2007;(153):20-7.
2007: Markolf Hanefeld; Gary A Herman; Mei Wu; Carolyn Mickel; Matilde Sanchez; Peter P Stein
Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.
Current medical research and opinion 2007;23(6):1329-39.
2007: Philip Home; Nigel P Jones; Stuart J Pocock; Henning Beck-Nielsen; Ramón Gomis; Markolf Hanefeld; Michel Komajda; P Curtis
Rosiglitazone RECORD study: glucose control outcomes at 18 months.
Diabetic medicine : a journal of the British Diabetic Association 2007;24(6):626-34.
2007: Elena Henkel; Sarsta Gallo; Gabriele Siegert; Carsta Koehler; Markolf Hanefeld
Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysis.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2007;18(4):327-34.
2007: Frank Pistrosch; Eva Reissmann; Jan Wildbrett; Carsta Koehler; Markolf Hanefeld
Relationship between diurnal blood pressure variation and diurnal blood glucose levels in type 2 diabetic patients.
American journal of hypertension 2007;20(5):541-5.
2007: Thomas Forst; Andreas Pfützner; Georg Lübben; Matthias Weber; Nikolaus Marx; Efstrathios Karagiannis; Carsta Koehler; Werner Baurecht; Cloth Hohberg; Markolf Hanefeld
Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study.
Metabolism: clinical and experimental 2007;56(4):491-6.
2007: Markolf Hanefeld; F Schaper; A Ceriello
[History and definition(s) of metabolic syndrome].
Der Internist 2007;48(2):117-25.
2007: Markolf Hanefeld; Nikolaus Marx; Andreas Pfützner; Werner Baurecht; Georg Lübben; Efstrathios Karagiannis; Ulf Stier; Thomas Forst
Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.
Journal of the American College of Cardiology 2007;49(3):290-7.
2007: Markolf Hanefeld
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes.
Cardiovascular diabetology 2007;6():20.
2007: Markolf Hanefeld; Carsta Koehler; Silvina Gallo; Inge Benke; Petra Ott
Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study.
Cardiovascular diabetology 2007;6():13.
2007: Louis Monnier; Claude Colette; Lawrence Leiter; Antonio Ceriello; Markolf Hanefeld; David Owens; Naoko Tajima; Jaakko Tuomiletho; Jaime Davidson
The effect of glucose variability on the risk of microvascular complications in type 1 diabetes.
Diabetes care 2007;30(1):185-6; author reply 187-8.
2007: Markolf Hanefeld; Rita Patwardhan; Nigel P Jones
A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes.
Nutrition, metabolism, and cardiovascular diseases : NMCD 2007;17(1):13-23.
2006: Markolf Hanefeld
[The metabolic syndrome: where are we going and for what benefits?].
Deutsche medizinische Wochenschrift (1946) 2006;131 Suppl 8():S236-9.
2006: Antonio Ceriello; Jamie Davidson; Markolf Hanefeld; Lawrence Leiter; Louis Monnier; David Owens; Naoko Tajima; Jaakko Tuomilehto
Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update.
Nutrition, metabolism, and cardiovascular diseases : NMCD 2006;16(7):453-6.
2006: Frank Pistrosch; C Koehler; Jan Wildbrett; Markolf Hanefeld
Relationship between diurnal glucose levels and HbA1c in type 2 diabetes.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2006;38(7):455-9.
2006: P E H Schwarz; Gordon W Towers; Sabine Fischer; Suresh Govindarajalu; Jan Schulze; Stefan R Bornstein; Markolf Hanefeld; Francis Vasseur
Hypoadiponectinemia is associated with progression toward type 2 diabetes and genetic variation in the ADIPOQ gene promoter.
Diabetes care 2006;29(7):1645-50.
2006: Markolf Hanefeld; A Pfützner; Thomas Forst; Georg Lübben
Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study.
Current medical research and opinion 2006;22(6):1211-5.
2006: Markolf Hanefeld; Wolfgang Metzler; Carsta Köhler; Frank Schaper
[Metabolic syndrome: "common soil" for diabetes and atherosclerosis. Novel approaches to an integrated therapy].
Herz 2006;31(3):246-54; quiz 255.
2006: Christof Kazda; Hiltrud Hülstrunk; Karin Helsberg; Frank Langer; Thomas Forst; Markolf Hanefeld
Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy.
Journal of diabetes and its complications 2006;20(3):145-52.
2006: Markolf Hanefeld
Treatment of impaired glucose tolerance with acarbose and its effect on intima-media thickness: a substudy of the STOP-NIDDM trial (study to prevent non-insulin-dependent diabetes mellitus).
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2006;12 Suppl 1():56-9.
2005: Markolf Hanefeld; Frank Schaper
Prandial hyperglycemia: is it important to track and treat?
Current diabetes reports 2005;5(5):333-9.
2005: Elena Henkel; Mario Menschikowski; Carsta Koehler; Wolfgang Leonhardt; Markolf Hanefeld
Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
Metabolism: clinical and experimental 2005;54(9):1168-73.
2005: Markolf Hanefeld
Introduction: new approaches to managing diabetic dyslipidaemia.
Atherosclerosis. Supplements 2005;6(3):1-2.
2005: Philip Home; Stuart J Pocock; Henning Beck-Nielsen; Ramón Gomis; Markolf Hanefeld; H Dargie; Michel Komajda; J Gubb; N Biswas; Nigel P Jones
Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol.
Diabetologia 2005;48(9):1726-35.
2005: Markolf Hanefeld; Robert G Josse; Jean-Louis Chiasson
Alpha-glucosidase inhibitors for patients with type 2 diabetes: response to van de Laar et al.
Diabetes care 2005;28(7):1840; author reply 1841.
2005: Antonio Ceriello; Markolf Hanefeld; Lawrence Leiter; L Monnier; D Owens; N Tajima; Jaakko Tuomilehto
To: Strey CH, Young J, Collier M, Florkowski CM, Shand BI, Scott RS (2004) The postprandial state does not impair endothelial function in women with Type 2 diabetes irrespective of glycaemic control. Diabetologia 47:1838-1846.
Diabetologia 2005;48(7):1423-4; author reply 1425-6.
2005: B H Charbonnel; David R Matthews; Guntram Schernthaner; Markolf Hanefeld; Paolo Brunetti
A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
Diabetic medicine : a journal of the British Diabetic Association 2005;22(4):399-405.
2005: David R Matthews; B H Charbonnel; Markolf Hanefeld; Paolo Brunetti; Guntram Schernthaner
Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study.
Diabetes/metabolism research and reviews 2005;21(2):167-74.
2005: Markolf Hanefeld
[Glucose-independent impact of the glitazones on the cardiovascular outcome].
MMW Fortschritte der Medizin 2005;147(1-2):37-9.
2005: Lawrence A Leiter; Antonio Ceriello; Jaime A Davidson; Markolf Hanefeld; Louis Monnier; David R Owens; Naoko Tajima; Jaakko Tuomilehto
Postprandial glucose regulation: new data and new implications.
Clinical therapeutics 2005;27 Suppl B():S42-56.
2005: Markolf Hanefeld
Outcome studies in type 2 diabetes.
Current medical research and opinion 2005;21 Suppl 1():S41-8.
2004: Antonio Ceriello; Markolf Hanefeld; Lawrence Leiter; Louis Monnier; Alan Moses; David Owens; Naoko Tajima; Jaakko Tuomilehto
Postprandial glucose regulation and diabetic complications.
Archives of internal medicine 2004;164(19):2090-5.
2004: Markolf Hanefeld; C Köhler
[Screening, prevention and early therapy of type 2 diabetics].
MMW Fortschritte der Medizin 2004;146(35-36):28-9, 31.
2004: Theodora Temelkova-Kurktschiev; Markolf Hanefeld; Giulia Chinetti; Christophe Zawadzki; Stéphan Haulon; Agata Kubaszek; Carsta Koehler; Wolfgang Leonhardt; Bart Staels; Markku Laakso
Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis.
The Journal of clinical endocrinology and metabolism 2004;89(9):4238-42.
2004: Markolf Hanefeld; Frank Schaper
[Postprandial hyperglycemia as a risk factor for cardiovascular disease. Therapy improves prognosis].
Herz 2004;29(5):480-7.
2004: Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.
Diabetologia 2004;47(6):969-75; discussion 976-7.
2004: Katharina Karrei; Carsta Koehler; Markolf Hanefeld; Theodora Temelkova-Kurktschiev; Stefano Del Prato
Fluctuations in glycaemia in clinical diabetes mellitus type 2 are not associated with carotid intima-media thickening.
Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease 2004;1(1):51-2.
2004: Markolf Hanefeld; Jean Louis Chiasson; Carsta Koehler; Elena Henkel; Frank Schaper; Theodora Temelkova-Kurktschiev
Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance.
Stroke; a journal of cerebral circulation 2004;35(5):1073-8.
2004: Theodora Temelkova-Kurktschiev; Markolf Hanefeld
The lipid triad in type 2 diabetes - prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2004;112(2):75-9.
2004: Frank Pistrosch; Jens Passauer; Sabine Fischer; Katja Fuecker; Markolf Hanefeld; Peter Gross
In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control.
Diabetes care 2004;27(2):484-90.
2004: Markolf Hanefeld; Paolo Brunetti; Guntram Schernthaner; David R Matthews; Bernard H Charbonnel
One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.
Diabetes care 2004;27(1):141-7.
2004: Markolf Hanefeld; M Cagatay; T Petrowitsch; Dieter Neuser; Dieter Petzinna; M Rupp
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.
European heart journal 2004;25(1):10-6.
2003: W Metzler; K Fücker; Uta Schwanebeck; Markolf Hanefeld; Ulrich Julius; B Kindel; Sabine Fischer
[Significance of triglycerides for other metabolic parameters in the familial metabolic syndrome].
Deutsche medizinische Wochenschrift (1946) 2003;128(38):1941-6.
2003: Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
JAMA : the journal of the American Medical Association 2003;290(4):486-94.
2003: Markolf Hanefeld; Carsta Koehler; Katja Fuecker; Elena Henkel; Frank Schaper; Theodora Temelkova-Kurktschiev
Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study.
Diabetes care 2003;26(3):868-74.
2003: Markolf Hanefeld; Sabine Fischer
[Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].
MMW Fortschritte der Medizin 2003;145(9):30-4.
2003: Sabine Fischer; A Patzak; H Rietzsch; Uta Schwanebeck; Carsta Köhler; Jan Wildbrett; Katja Fuecker; Theodora Temelkova-Kurktschiev; Markolf Hanefeld
Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients.
Diabetes, obesity & metabolism 2003;5(1):38-44.
2002: Markolf Hanefeld; G Sachse
The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial.
Diabetes, obesity & metabolism 2002;4(6):415-23.
2002: Theodora Temelkova-Kurktschiev; Carsta Koehler; Elena Henkel; Markolf Hanefeld
Leukocyte count and fibrinogen are associated with carotid and femoral intima-media thickness in a risk population for diabetes.
Cardiovascular research 2002;56(2):277-83.
2002: Markolf Hanefeld
[In high risk for diabetes should drugs be used for prevention? (interview by Dr. Judith Neumaier)].
MMW Fortschritte der Medizin 2002;144(40):12.
2002: Steffi Kopprasch; Jens Pietzsch; Eberhard Kuhlisch; Katja Fuecker; Theodora Temelkova-Kurktschiev; Markolf Hanefeld; Helmut Kühne; Ulrich Julius; Juergen Graessler
In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance.
Diabetes 2002;51(10):3102-6.
2002: Sabine Fischer; Markolf Hanefeld; Steven M Haffner; C Fusch; Uta Schwanebeck; Carsta Köhler; K Fücker; Ulrich Julius
Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass.
Acta diabetologica 2002;39(3):105-10.
2002: Markolf Hanefeld; Sabine Fischer
[Differential type 2 diabetes therapy based on pathophysiological aspects].
Therapeutische Umschau. Revue thérapeutique 2002;59(8):393-401.
2002: Markolf Hanefeld
Postprandial hyperglycaemia: noxious effects on the vessel wall.
International journal of clinical practice. Supplement 2002;(129):45-50.
2002: Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
Lancet 2002;359(9323):2072-7.
2002: M Kaiser; Theodora Temelkova-Kurktschiev; Markolf Hanefeld
Intima-media thickness and atherosclerotic plaques in familial defective apolipoprotein B-100 and familial hypercholesterolemia.
Annals of the New York Academy of Sciences 2002;967():528-34.
2002: Theodora Temelkova-Kurktschiev; Gabriele Siegert; S Bergmann; Elena Henkel; Carsta Koehler; Werner Jaross; Markolf Hanefeld
Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes.
Metabolism: clinical and experimental 2002;51(6):743-9.
2002: Elena Henkel; Carsta Köhler; Theodora Temelkova-Kurktschiev; Markolf Hanefeld
[Predictors of abnormal glucose tolerance in persons at risk of type 2 diabetes: the RIAD study].
Deutsche medizinische Wochenschrift (1946) 2002;127(18):953-7.
2002: Markolf Hanefeld; Theodora Temelkova-Kurktschiev
Control of post-prandial hyperglycemia--an essential part of good diabetes treatment and prevention of cardiovascular complications.
Nutrition, metabolism, and cardiovascular diseases : NMCD 2002;12(2):98-107.
2002: Elena Henkel; Theodora Temelkova-Kurktschiev; Carsta Koehler; Jens Pietzsch; Wolfgang Leonhardt; Markolf Hanefeld
Impaired glucose tolerance is not associated with lipid intolerance.
Diabetes, nutrition & metabolism 2002;15(2):84-90.
2002: Markolf Hanefeld; Carsta Köhler
[The metabolic syndrome and its epidemiologic dimensions in historical perspective].
Zeitschrift für ärztliche Fortbildung und Qualitätssicherung 2002;96(3):183-8.
2002: Markolf Hanefeld; Steven M Haffner; Mario Menschikowski; Carsta Koehler; Theodora Temelkova-Kurktschiev; Jan Wildbrett; Sabine Fischer
Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes.
Diabetes research and clinical practice 2002;55(3):221-7.
2002: Theodora Temelkova-Kurktschiev; Markolf Hanefeld
Oral glucose tolerance test: to be or not to be performed?
Clinical laboratory 2002;48(3-4):143-52.
2002: Theodora Temelkova-Kurktschiev; Elena Henkel; Carsta Koehler; K Karrei; Markolf Hanefeld
Subclinical inflammation in newly detected Type II diabetes and impaired glucose tolerance.
Diabetologia 2002;45(1):151.
2001: Elena Henkel; Markolf Hanefeld
[Hyperlipidemia and fibrates with special reference to diabetes].
Herz 2001;26(8):523-30.
2001: Markolf Hanefeld; G Belcher
Safety profile of pioglitazone.
International journal of clinical practice. Supplement 2001;(121):27-31.
2001: Markolf Hanefeld
Pharmacokinetics and clinical efficacy of pioglitazone.
International journal of clinical practice. Supplement 2001;(121):19-25.
2001: Markolf Hanefeld
[The new oral antidiabetics. Type 2 diabetes under control only with tablets?].
MMW Fortschritte der Medizin 2001;143(21):38-42.
2001: Theodora Temelkova-Kurktschiev; Elena Henkel; Carsta Koehler; Markolf Hanefeld
Light-to-moderate alcohol consumption, risk factor profile and early atherosclerosis: the RIAD study.
Atherosclerosis 2001;156(1):239-40.
2001: Theodora Temelkova-Kurktschiev; S Fischer; Carsta Koehler; G Mennicken; Elena Henkel; Markolf Hanefeld
[Intima-media thickness in healthy probands without risk factors for arteriosclerosis].
Deutsche medizinische Wochenschrift (1946) 2001;126(8):193-7.
2000: Markolf Hanefeld; Carsta Koehler; Elena Henkel; Katja Fuecker; Frank Schaper; Theodora Temelkova-Kurktschiev
Post-challenge hyperglycaemia relates more strongly than fasting hyperglycaemia with carotid intima-media thickness: the RIAD Study. Risk Factors in Impaired Glucose Tolerance for Atherosclerosis and Diabetes.
Diabetic medicine : a journal of the British Diabetic Association 2000;17(12):835-40.
2000: Theodora Temelkova-Kurktschiev; Carsta Koehler; Elena Henkel; Wolfgang Leonhardt; Katja Fuecker; Markolf Hanefeld
Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level.
Diabetes care 2000;23(12):1830-4.
2000: Markolf Hanefeld
Post-prandial hyperglycaemia and vascular disease.
International journal of clinical practice. Supplement 2000;(112):13-8.
2000: Birgit Noack; I Jachmann; S Roscher; L Sieber; Steffi Kopprasch; Christian Lück; Markolf Hanefeld; Thomas Hoffmann
Metabolic diseases and their possible link to risk indicators of periodontitis.
Journal of periodontology 2000;71(6):898-903.
2000: Markolf Hanefeld; K P Bouter; S Dickinson; C Guitard
Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.
Diabetes care 2000;23(2):202-7.
2000: A Pixa; Jens Pietzsch; Ulrich Julius; Mario Menschikowski; Markolf Hanefeld
Impaired glucose tolerance (IGT) is not associated with disturbed homocysteine metabolism.
Amino acids 2000;18(3):289-98.
2000: Theodora Temelkova-Kurktschiev; Elena Henkel; Frank Schaper; Carsta Koehler; Gabriele Siegert; Markolf Hanefeld
Prevalence and atherosclerosis risk in different types of non-diabetic hyperglycemia. Is mild hyperglycemia an underestimated evil?
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2000;108(2):93-9.
1999: Jens Pietzsch; Ulrich Julius; Markolf Hanefeld
Metabolic basis of low high density lipoprotein in subjects with impaired glucose tolerance.
Annals of the New York Academy of Sciences 1999;892():323-6.
1999: Jens Pietzsch; Ulrich Julius; C Kirch; Sabine Fischer; Markolf Hanefeld
Very low density lipoprotein overproduction is maximally expressed in early insulin resistant states.
Annals of the New York Academy of Sciences 1999;892():319-22.
1999: Siegmund Gehrisch; Heike Kostka; M Tiebel; A Patzak; A Paetzold; Ulrich Julius; Hans-Egbert Schroeder; Markolf Hanefeld; Werner Jaross
Mutations of the human hepatic lipase gene in patients with combined hypertriglyceridemia/hyperalphalipoproteinemia and in patients with familial combined hyperlipidemia.
Journal of molecular medicine (Berlin, Germany) 1999;77(10):728-34.
1999: Carsta Köhler; Theodora Temelkova-Kurktschiev; Frank Schaper; K Fücker; Markolf Hanefeld
[Prevalence of newly diagnosed type 2 diabetes, impaired glucose tolerance and abnormal fasting glucose in a high risk population. Data from the RIAD study using new diagnostic criteria for diabetes].
Deutsche medizinische Wochenschrift (1946) 1999;124(37):1057-61.
1999: Markolf Hanefeld; Carsta Koehler; Frank Schaper; Katja Fuecker; Elena Henkel; Theodora Temelkova-Kurktschiev
Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals.
Atherosclerosis 1999;144(1):229-35.
1999: Wolfgang Leonhardt; Markolf Hanefeld; Frank Schaper
Diminished susceptibility to in vitro oxidation of low-density lipoproteins in hypercholesterolemia: key role of alpha-tocopherol content.
Atherosclerosis 1999;144(1):103-7.
1999: Carsta Koehler; Theodora Temelkova-Kurktschiev; Elena Henkel; Frank Schaper; Katja Fuecker; Markolf Hanefeld
Is the newly suggested fasting plasma glucose cut-off point for the diagnosis of diabetes the right one?
Diabetologia 1999;42(5):635-6.
1999: J Wildbrett; M Nagel; F Theissig; H J Gaertner; S Gromeier; S Fischer; Markolf Hanefeld
[An unusual picture of insulinoma in type-2 diabetes mellitus and morbid obesity].
Deutsche medizinische Wochenschrift (1946) 1999;124(9):248-52.
1999: Markolf Hanefeld; Theodora Temelkova-Kurktschiev; Frank Schaper; Elena Henkel; Gabriele Siegert; Carsta Koehler
Impaired fasting glucose is not a risk factor for atherosclerosis.
Diabetic medicine : a journal of the British Diabetic Association 1999;16(3):212-8.
1999: Theodora Temelkova-Kurktschiev; Carsta Koehler; Wolfgang Leonhardt; Frank Schaper; Elena Henkel; Gabriele Siegert; Markolf Hanefeld
Increased intimal-medial thickness in newly detected type 2 diabetes: risk factors.
Diabetes care 1999;22(2):333-8.
1999: M Breidert; Gunter Haroske; S Gromeier; U Dziambor; Markolf Hanefeld
[Bone pain in the last pregnancy trimester].
Der Internist 1999;40(1):100-4.
1999: Wolfgang Leonhardt; R Horn; G Brabant; M Breidert; Theodora Temelkova-Kurktschiev; K Fücker; Markolf Hanefeld
Relation of free and specifically bound leptin to insulin secretion in patients with impaired glucose tolerance (IGT).
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 1999;107(1):46-52.
1998: Jens Pietzsch; Ulrich Julius; S Nitzsche; Markolf Hanefeld
In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance.
Diabetes 1998;47(12):1928-34.
1998: Jean-Louis Chiasson; Ramon Gomis; Markolf Hanefeld; Robert G Josse; Avraham Karasik; Markku Laakso
The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
Diabetes care 1998;21(10):1720-5.
1998: Markolf Hanefeld; Theodora Temelkova-Kurktschiev
Commercially sponsored supplements.
Diabetic medicine : a journal of the British Diabetic Association 1998;15(8):707-8.
1998: Markolf Hanefeld
The role of acarbose in the treatment of non-insulin-dependent diabetes mellitus.
Journal of diabetes and its complications 1998;12(4):228-37.
1998: Theodora Temelkova-Kurktschiev; Carsta Koehler; Frank Schaper; Elena Henkel; A Hahnefeld; Katja Fuecker; Gabriele Siegert; Markolf Hanefeld
Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima media thickness in non-diabetic individuals.
Diabetologia 1998;41(6):706-12.
1998: K Banz; R Dinkel; Markolf Hanefeld; U Schwanebeck
Evaluation of the potential clinical and economic effects of bodyweight stabilisation with acarbose in patients with type 2 diabetes mellitus. A decision-analytical approach.
PharmacoEconomics 1998;13(4):449-59.
1998: Sabine Fischer; Markolf Hanefeld; M Spengler; K Boehme; Theodora Temelkova-Kurktschiev
European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses.
Acta diabetologica 1998;35(1):34-40.
1998: M Breidert; Theodora Temelkova-Kurktschiev; Markolf Hanefeld; Wolfgang Leonhardt; A Schmoeckel; Jochen Seissler
Prevalence of diabetes-specific autoantibodies in patients at risk for adult onset diabetes mellitus.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 1998;106(2):113-6.
1997: Theodora Temelkova-Kurktschiev; Markolf Hanefeld; Wolfgang Leonhardt
Small dense low-density lipoprotein (LDL) in non-insulin-dependent diabetes mellitus (NIDDM). Impact of hypertriglyceridemia.
Annals of the New York Academy of Sciences 1997;827():279-86.
1997: Markolf Hanefeld; Theodora Temelkova-Kurktschiev; C Köhler
Effect of oral antidiabetics and insulin on lipids and coronary heart disease in non-insulin-dependent diabetes mellitus.
Annals of the New York Academy of Sciences 1997;827():246-68.
1997: Markolf Hanefeld; Theodora Temelkova-Kurktschiev
The postprandial state and the risk of atherosclerosis.
Diabetic medicine : a journal of the British Diabetic Association 1997;14 Suppl 3():S6-11.
1997: Markolf Hanefeld; H Schmechel; Uta Schwanebeck; J Lindner
Predictors of coronary heart disease and death in NIDDM: the Diabetes Intervention Study experience.
Diabetologia 1997;40 Suppl 2():S123-4.
1997: Jan Wildbrett; Markolf Hanefeld; K Fücker; Thomas Pinzer; S Bergmann; Gabriele Siegert; M Breidert
Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor I.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 1997;105(6):331-5.
1997: Jens Pietzsch; Ulrich Julius; Markolf Hanefeld
Stable isotope ratio analysis of amino acids: the use of N(O,S)-ethoxycarbonyl trifluoroethyl ester derivatives and gas chromatography/mass spectrometry.
Rapid communications in mass spectrometry : RCM 1997;11(17):1835-8.
1996: Markolf Hanefeld; S Fischer
[Rational therapy of Type II diabetes].
Therapeutische Umschau. Revue thérapeutique 1996;53(12):914-24.
1996: Markolf Hanefeld; S Fischer; Ulrich Julius; J Schulze; U Schwanebeck; H Schmechel; H J Ziegelasch; J Lindner
Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up.
Diabetologia 1996;39(12):1577-83.
1996: Wolfgang Leonhardt; Markolf Hanefeld; G Müller; C Hora; D Meissner; Peter Lattke; A Paetzold; Werner Jaross; H E Schroeder
Impact of concentrations of glycated hemoglobin, alpha-tocopherol, copper, and manganese on oxidation of low-density lipoproteins in patients with type I diabetes, type II diabetes and control subjects.
Clinica chimica acta; international journal of clinical chemistry 1996;254(2):173-86.
1996: Jens Pietzsch; B Wiedemann; Ulrich Julius; S Nitzsche; Siegmund Gehrisch; S Bergmann; Wolfgang Leonhardt; Werner Jaross; Markolf Hanefeld
Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B-100: a stable isotope approach.
Journal of lipid research 1996;37(10):2074-87.
1996: Ulrich Julius; Markolf Hanefeld
[Integrated drug therapy of the metabolic syndrome].
Der Internist 1996;37(7):722-30.
1996: Markolf Hanefeld; B Willms
[Diagnosis of the metabolic syndrome].
Der Internist 1996;37(7):705-11.
1996: Markolf Hanefeld; H Schmechel; Ulrich Julius; U Schwanebeck
Determinants for coronary heart disease in non-insulin-dependent diabetes mellitus: lessons from the diabetes intervention study.
Diabetes research and clinical practice 1996;30 Suppl():67-70.
1995: M Breidert; Thomas Pinzer; J Wildbrett; Stefan R Bornstein; Markolf Hanefeld
Long-term effect of octreotide in acromegaly on insulin resistance.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 1995;27(5):226-30.
1995: Jens Pietzsch; S Subat; S Nitzsche; Wolfgang Leonhardt; K U Schentke; Markolf Hanefeld
Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and composition.
Biochimica et biophysica acta 1995;1254(1):77-88.
1994: Wolfgang Leonhardt; Jens Pietzsch; Ulrich Julius; Markolf Hanefeld
Recovery of cholesterol and triacylglycerol in very-fast ultracentrifugation of human lipoproteins in a large range of concentrations.
European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies 1994;32(12):929-33.
1994: W Leonhardt; Markolf Hanefeld; S Fischer; J Schulze
Efficacy of alpha-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia.
European journal of clinical investigation 1994;24 Suppl 3():45-9.
1994: Ulrich Julius; H Fritsch; W Fritsch; E Rehak; K Fücker; Wolfgang Leonhardt; Markolf Hanefeld
Impact of hormone replacement therapy on postprandial lipoproteins and lipoprotein(a) in normolipidemic postmenopausal women.
The Clinical investigator 1994;72(7):502-7.
1992: Ulrich Julius; C Hora; P Gross; K Fücker; S Bergmann; Markolf Hanefeld
[Different effects of fibrates on the lipoprotein profile. Comparison of the effectiveness of gemfibrozil and bezafibrate in various types of hyperlipoproteinemia].
Fortschritte der Medizin 1992;110(35-36):669-72.
1992: J Lindner; H Schmechel; Markolf Hanefeld; U Schwanebeck; K Bauch
[Coronary heart disease and insulin concentration in type II diabetic patients--results of a diabetes intervention study].
Zeitschrift für die gesamte innere Medizin und ihre Grenzgebiete 1992;47(6):246-50.
1991: Markolf Hanefeld; S Fischer; J Schulze; M Spengler; M Wargenau; K Schollberg; K Fücker
Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone.
Diabetes care 1991;14(8):732-7.
1991: Markolf Hanefeld; S Fischer; H Schmechel; G Rothe; J Schulze; H Dude; U Schwanebeck; Ulrich Julius
Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM.
Diabetes care 1991;14(4):308-17.
1990: S Fischer; Markolf Hanefeld; P D Lang; K Fücker; S Bergmann; Siegmund Gehrisch; W Leonhardt; Werner Jaross
Efficacy of a combined bezafibrate retard-colestyramine treatment in patients with hypercholesterolemia.
Arzneimittel-Forschung 1990;40(4):469-72.
1989: Ulrich Julius; W Leonardt; D Noack; J Schulze; N G Nikulcheva; Werner Jaross; Markolf Hanefeld
Pathogenetic role of adipose tissue lipase deficit for development of hypertriglyceridaemia.
Experimental and clinical endocrinology 1989;94(1-2):187-93.
1989: H Schmechel; J Schulze; Markolf Hanefeld; C Lippold; U Schwanebeck; G Rössger; H Haller
[Coronary heart diseases and associated risk factors in newly manifested type II diabetic patients over the course of 5 years].
Zeitschrift für die gesamte innere Medizin und ihre Grenzgebiete 1989;44(6):172-5.
1989: Markolf Hanefeld; M Weck
Very low calorie diet therapy in obese non-insulin dependent diabetes patients.
International journal of obesity 1989;13 Suppl 2():33-7.
1989: M Weck; Markolf Hanefeld; K Schollberg
Effects of VLCD in obese NIDDM (non-insulin dependent diabetes) on glucose, insulin and C-peptide dynamics.
International journal of obesity 1989;13 Suppl 2():159-60.
1988: Markolf Hanefeld; P D Lang; S Fischer; W Leonhardt; S Bergmann; Werner Jaross
Effects of a bezafibrate sustained release formulation on plasma lipoproteins in patients with hypercholesterolemia. Importance of timing of tablet intake for efficacy.
Arzneimittel-Forschung 1988;38(12):1835-7.
1988: H Schmechel; J Schulze; Markolf Hanefeld; Ulrich Julius; U Schwanebeck; C Lippold
[The value of hypertension and metabolic factors on the development of coronary heart disease in type II diabetic patients].
Zeitschrift für die gesamte innere Medizin und ihre Grenzgebiete 1988;43(23):669-74.
1988: J Beitz; K Schollberg; S Fischer; Werner Jaross; Markolf Hanefeld; H J Mest
Is the level of steroid hormones in the low density lipoprotein (LDL) particles responsible for the prostaglandin I2 inhibitory potency of LDL?
Biomedica biochimica acta 1988;47(2):181-7.
1987: M Weck; S Fischer; Markolf Hanefeld; Wolfgang Leonhardt; Ulrich Julius; W Gräser; B Schneider; H Haller
Loss of fat, water, and protein during very low calorie diets and complete starvation.
Klinische Wochenschrift 1987;65(23):1142-50.
1987: Wolfgang Leonhardt; Markolf Hanefeld; Ulrich Julius; J Schulze; S Fischer; M Weck; H Haller
Predictive value of the index of desirable body weight for total body fat mass as measured by dilution of tritiated water--problems and limitations.
International journal of obesity 1987;11(3):221-8.
1986: H Schmechel; S Fischer; C Lippold; J Schulze; Markolf Hanefeld; H Haller
[Cardiologic findings in newly manifested type II diabetics of the diabetes intervention study].
Zeitschrift für die gesamte innere Medizin und ihre Grenzgebiete 1986;41(9):256-60.
1985: S Fischer; Markolf Hanefeld; M Weck; H Beckert; Ulrich Julius; D Eichhorn; G Rothe; Wolfgang Leonhardt; K Graeser; H Haller
[Results of protein-sparing modified fasting in hyperlipoproteinemias].
Deutsche Zeitschrift für Verdauungs- und Stoffwechselkrankheiten 1985;45(5):228-35.
1985: Markolf Hanefeld; J Schulze; S Fischer; Ulrich Julius; H Schmechel; H Haller
The Diabetes Intervention Study (DIS): a cooperative multi-intervention trial with newly manifested type II diabetics: preliminary results.
Monographs on atherosclerosis 1985;13():98-103.
1984: Markolf Hanefeld; C Hora; J Schulze; G Rothe; U Barthel; H Haller
Reduced incidence of cardiovascular complications and mortality in hyperlipoproteinemia (HLP) with effective lipid correction. The Dresden HLP study.
Atherosclerosis 1984;53(1):47-58.
1984: G Honigmann; E Schimke; V Schliack; J Beitz; W Förster; S Fischer; C Hora; Markolf Hanefeld
Fatty acid composition and action of serum lipoproteins on the PGI2-formation after various oil diets in hyperlipoproteinemia.
Biomedica biochimica acta 1984;43(8-9):S443-6.
1984: S Fischer; G Honigmann; C Hora; E Schimke; J Beitz; Markolf Hanefeld; Wolfgang Leonhardt; H Haller; W Förster; V Schliack
[Results of linseed oil and olive oil therapy in hyperlipoproteinemia patients].
Deutsche Zeitschrift für Verdauungs- und Stoffwechselkrankheiten 1984;44(5):245-51.
1982: C Hora; Markolf Hanefeld; Wolfgang Leonhardt; F Jacob; H Haller
[The relation between lipoprotein fractions, sex and IHD in patients with primary hyperlipoproteinemia].
Zeitschrift für die gesamte innere Medizin und ihre Grenzgebiete 1982;37(23):801-4.
1981: M Weck; Markolf Hanefeld; M Zschornack; S Fischer; C Hora
[Physical training in obesity].
Zeitschrift für ärztliche Fortbildung 1981;75(23):1103-6.